Sunshine Biopharma Registers 25.5M Warrant Shares, Flags Nasdaq Delisting Risk
SBFM is trading near its 52-week low of $1.01 (9.9% above the low).
Summary
Sunshine Biopharma registered 25.5 million warrant shares for potential exercise at $1.2202, while disclosing it fails Nasdaq's proposed $5 million market value requirement and faces immediate delisting risk until June 2027.
Key Events · Financing and Capital Events · SBFM
-
Warrant Share Registration
Registered 25,477,133 shares underlying Series B Warrants at exercise price $1.2202, with maximum aggregate offering price of $31,087,198 if all warrants are exercised for cash.
-
Nasdaq Delisting Risk
Company does not currently meet Nasdaq's proposed $5 million Market Value of Listed Securities requirement and is subject to immediate delisting notice until June 2027 if it fails the $1.00 bid price rule for 30 consecutive business days.
-
Warrant Overhang
As of the prospectus date, the company has 29,512,762 outstanding warrants subject to adjustment, creating significant potential future dilution.
-
Use of Proceeds
If all Series B Warrants are exercised for cash, net proceeds would be approximately $31 million, intended for general corporate purposes including working capital.
Analysis · SBFM · Life Sciences
Sunshine Biopharma filed an S-1 to register 25,477,133 shares underlying its Series B Warrants at an exercise price of $1.2202, potentially raising up to $31.1 million if all warrants are exercised for cash. The filing also discloses that the company does not currently meet Nasdaq's proposed $5 million market value requirement and remains subject to immediate delisting notice until June 2027 if it fails the $1.00 bid price rule. With a market cap of only $4.46 million, the company is already below the proposed threshold, making the delisting risk acute. The registration itself does not dilute shareholders unless warrants are exercised, but the disclosure of listing non-compliance is a material governance red flag that could force a delisting and severely impair liquidity and capital-raising ability.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SBFM was trading at $1.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.5M. The 52-week trading range was $1.01 to $24.30. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.